Inclusion Criteria:

• Histologically documented adenocarcinoma of the prostate.

• Status post radical prostatectomy with sampling of the pelvic lymph nodes with histologically confirmed adenocarcinoma of the prostate, with at least 1 of 3 disease criteria which must be met as indicated below:

  • a) Pathologic T2N0M0 disease with positive margins and gleason score greater than or equal to 8
  • b) Pathologic T3aN0M0 disease with extracapsular extension and Gleason Score greater than equal to 8
  • c) Pathologic T3bN0M0 disease
• Undetectable PSA level less than or equal to 0.2 within 8 weeks after radical prostatectomy
• No prior chemotherapy, pelvic irradiation, or androgen ablation
• Karnofsky Performance Status greater than equal to 70
• Hematologic parameters must be within the following limits:
• WBC greater than equal to 3,000
• Platelet Count greater than equal to 130,000
• Hemoglobin level greater than equal to 11.0
• Creatinine less than equal to 2.5
• Normal liver function defined as the following: Total bilirubin below the upper limit of normal AND AST, ALT, and Alkaline Phosphatase must be within a defined range of eligibility.
• Patients with a history of an invasive malignancy within the last 5 years are not eligible for the protocol; patients who are NED from a prior invasive malignancy for at least 5 years or longer are eligible for the trial. Patients with history of benign tumors such as a pituitary macroadenomas, meningiomas, or craniopharyngiomas are eligible as long as the benign tumor is under local control regardless of the time frame. Patients with concurrent adequately treated basal cell or squamous cell carcinoma of the skin are also eligible for the protocol.
• Patients must be informed of the investigative nature of the treatment, must give appropriate informed consent to protocol procedures and must sign an Informed Consent Documentation Form.
• Must not have concomitant medical, psychological or social circumstances which would interfere with compliance with the protocol treatment and follow-up.
• Age greater than or equal to 18 years
• Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter, which should be for at least 6 months after the completion of protocol therapy

Exclusion Criteria:

• Patients who have received prior chemotherapy, pelvic irradiation or androgen ablation including neoadjuvant hormonal therapy prior to radical prostatectomy.
• Any coexisting medical condition precluding full compliance with the study.
• Patients with active infections or known infection with HIV.
• Psychological, familiar, sociological or geographical conditions which would not permit compliance with the study protocol.
• Known contraindication to dexamethasone
• Patients with a history of a hypersensitivity reaction to products containing Polysorbate 80